Strategic Demonstration of the Clinical Utility of Nontraditional Antibacterials.

Antimicrobial stewardship (AMS) interventions have curbed antibiotic misuse, paradoxically restricting market adoption of new antibiotics in the process. This review critically examines non-traditional approaches to manage bacterial infections, offering solutions to reinforce AMS without compromising the commercial viability of thes new agents. An analysis of the key value propositions, regulatory frameworks, and market access pathways is presented. Actionable strategies to overcome regulatory and commercial challenges towards integrating non-traditional agents into clinical guidelines and AMS policies are highlighted.